Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gyros Completes Next Stage of Development Program with Expansion of Product Portfolio

Published: Friday, August 05, 2011
Last Updated: Thursday, August 04, 2011
Bookmark and Share
Company announces availability of software modules and services to strengthen support for scientists using the Gyros immunoassay platform in regulated environments.

Gyros AB, has announced the completion of a development program initiated to fulfill the requirements of scientists using the Company’s immunoassay platform in the biopharmaceutical industry.

The development program has seen the release of a number of software modules and services to augment the company’s product portfolio, to provide enhanced functionality for users of Gyrolab™ xP workstations, and to further facilitate the use of the platform in regulated environments.

Software modules, such as the Gyrolab LIMS Interface to enable networking and Gyrolab Control Report to generate non-editable result files of raw data, as demanded by regulatory authorities, enable users to upgrade their workstations and retain 21 CFR Part 11 compliance.

Also available is a Gyrolab Functionality Check Kit to check instrument performance within minutes - again in compliance with regulatory demands. To save more time, the Company also offers support for Installation Qualification/Operational Qualification (IQ/OQ) and Performance Qualification (PQ) guidance.

Attendees at the recent European Gyrolab Seminar were able to preview the latest release: the Gyrolab Viewer module that enables the binding profile of each data point to be displayed together with sample and run information.

The ability to see and compare individual binding profiles, a unique feature of the Gyros immunoassay platform, enables users to easily and quickly select optimal reagents during assay development as well as providing a troubleshooting tool for quality control.

Commenting on the announcement, Erik Walldén, President and Chief Executive Officer of Gyros AB, said: “An international installed base confirms that our immunoassay platform is becoming an established technology for bioanalysis throughout the biotherapeutic workflow. It is therefore critical to ensure that our clients have all the support they need to transfer immunoassays downstream from research and development through to regulated GxP environments or between sites. As well as broadening our product offering, this program supports our long term objective of setting the industry standard for transforming the performance of immunoassays within the biopharmaceutical industry.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gyros Announces Changes to its Management Team
Dr. Jon-Sverre Schanche becomes Chief Technology Officer and Vice President Technical Affairs.
Monday, October 24, 2011
Gyros Wins SwedenBIO Award 2011
Company selected to receive the award based on the international success of the Gyros immunoassay platform.
Friday, May 27, 2011
Gyros platform enters leading US Clinical Research Organization
CEDRA Corporation, a division of Worldwide Clinical Trials, invests in Gyrolab workstation
Tuesday, March 16, 2010
Gyros Platform Ramps Up Immunoassay Capacity at ICON Development Solutions
CRO purchases third Gyrolab workstation to develop and run immunoassays.
Friday, March 12, 2010
Gyros and SCRUM Sign Distribution Agreement for the Japanese Market
SCRUM will market, sell and fully support the Gyros product range, within the Japanese life-science market industries.
Wednesday, February 17, 2010
Gyros has Completed the Separate Sales of two Microfluidic System Platforms
Gyros platform for protein quantification is purchased by AstraZeneca and Cambridge Antibody Technology.
Wednesday, August 09, 2006
Gyros Awarded Frost & Sullivan Technology of the Year Award
The award recognizes the company’s technology development and overall technical excellence.
Wednesday, November 16, 2005
Gyros AB licenses technology to Cellectricon AB

Tuesday, April 15, 2003
Gyros expands with German office

Monday, December 02, 2002
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
'Kidney on a Chip' Facilitates Safer Drug Dosing
University of Michigan researchers have used a "kidney on a chip" device to mimic the flow of medication through human kidneys and measure its effect on kidney cells.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Experimental Therapy For Brain Cancer Could Prevent Drug Resistance
Information from penny-sized microfluidic chips allowed researchers to anticipate resistance to cancer treatment.
3D Printing of Lego Fluidics
Study shows how 3D printing can open up microfluidic technology to a wider audience.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!